University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Faculty Publications and Other Works -Biomedical and Diagnostic Sciences

Veterinary Medicine -- Faculty Publications and
Other Works

2018

Determination of Hydromorphone in Bearded Dragon Plasma
Using LC-MS Detection
Sherry Cox
University of Tennessee, Knoxville

Chelsey Fortner
University of Tennessee, Knoxville

Rebecca Davis
University of Tennessee, Knoxville

Joan Bergman
University of Tennessee, Knoxville

Kurt Sladky
University of Wisconsin

Follow this and additional works at: https://trace.tennessee.edu/utk_compmedpubs

Recommended Citation
Cox, Sherry; Fortner, Chelsey; Davis, Rebecca; Bergman, Joan; and Sladky, Kurt, "Determination of
Hydromorphone in Bearded Dragon Plasma Using LC-MS Detection" (2018). Faculty Publications and
Other Works -- Biomedical and Diagnostic Sciences.
https://trace.tennessee.edu/utk_compmedpubs/156

This Poster is brought to you for free and open access by the Veterinary Medicine -- Faculty Publications and Other
Works at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Faculty
Publications and Other Works -- Biomedical and Diagnostic Sciences by an authorized administrator of TRACE:
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.

Determination of Hydromorphone in Bearded Dragon Plasma Using LC-MS Detection
Sherry Cox, Chelsey Fortner, Rebecca Davis, Joan Bergman, Kurt Sladky*
University of Tennessee College of Veterinary Medicine, *University of Wisconsin
Chromatographic conditions and apparatus
The scan rate was 2 pts/s, gain 1, capillary voltage
0.6 kV, cone voltage 12, ion source temperature
150˚C and probe temperature 600˚C. Nitrogen was
used as the nebulizing gas. Hydromorphone was
detected at 286.10 m/z and naltrexone was
detected at 342.41 m/z.

Materials & Methods

Abstract

A new method of analysis has been developed and
validated for the determination of hydromorphone
in bearded dragon plasma. Following SPE, samples
were separated by reversed-phase HPLC on an
Atlantis T3 column (4.6 x 150 mm, 3 µm) and
detected by MS. The mobile phase was a mixture of
water with 0.1% formic acid, and acetonitrile with
0.1% formic acid (91:9), with a flow rate of 0.7
mL/min. The procedure produced a linear curve
over the concentration range of 1 to 500 ng/mL with
an LOQ of 1 ng/mL and LOD of 0.5 ng/mL. Intra- and
inter-assay variability ranged from 3.9% - 9.3% and
the average recovery for hydromorphone was 91%.
The average recovery for naltrexone, which was the
internal standard, was 90%. This method has been
developed in bearded dragon plasma and should be
applicable to other species, it should also be useful
to those investigators dealing with small volumes,
particularly when conducting PK studies that require
multiple sampling from the same animal.

Introduction

Recognition of pain and appropriate analgesic
therapy is becoming increasingly important in
veterinary medicine. Opioids are a diverse group of
drugs that bind to specific receptors in the brain,
spinal cord, and peripheral tissues. They are used for
their analgesic properties, acting on the µ-, κ-, and
δ-opioid receptors in the CNS and peripheral
nervous system. Hydromorphone is a semi-synthetic
µ-opioid receptor agonist with a potency of five to
seven times that of morphine. It is used frequently
in small animal anesthesia and for pain management
because of its low cost and apparent efficacy and
safety history. In addition, hydromorphone is an
accepted alternative to morphine because it does
not cause histamine release after IV administration.

Reagents & Standards
Hydromorphone and naltrexone were purchased
from USP. All other reagent grade chemicals and
solvents were purchased from Fisher Scientific.
Stock solutions of hydromorphone (100 µg/mL)
and naltrexone (100 µg/mL, internal standard) were
prepared in methanol. Dilutions in methanol were
prepared to produce 0.01, 0.1, and 1 µg/mL working
stocks. All solutions were stored at -20˚C. By
comparing standard areas over time it was
determined that they were stable for six months.
For preparation of calibration standards and
quality control (QC) samples, appropriate aliquots of
the working stock solutions were placed in tubes,
evaporated to dryness with nitrogen, and then
dissolved in 100 µL of untreated plasma. The plasma
was obtained from drug free healthy animals. The
final concentrations were 1, 2.5, 5, 10, 25, 50, 100,
250 and 500 ng/mL for calibration standards and
3.5, 15, 35, 75, 150 and 350 µg/mL for QC samples.
Linearity was assessed by linear regression
analysis. The calibration curve had a correlation
coefficient of 0.99 or better. The acceptance
criterion for each back-calculated standard and QC
concentration was 15% deviation from the nominal
value except the lower limit of quantification (LOQ)
which was set at 20%.
Chromatographic conditions and apparatus
The chromatography system consisted of a 2695
separation module and an Acuity QDa singlequadrupole mass detector (Waters). The compounds
were separated on an Atlantis T3 (4.6 x 150 mm, 3
µm) column preceded by a 3 µm Atlantis T3 guard
column. The mobile phase was a mixture of (A):
water with 0.1% formic acid and (B) acetonitrile with
0.1% formic acid (91:9). The mixture was pumped at
a starting gradient of 91% A and 9% B and held for 4
minutes and then was adjusted to 85% A and 15% B
over 6 min, and back to initial conditions over 3 min.
The flow rate was 0.70 mL/min, and the column
temperature was 30˚C. The compounds were
detected by positive selected ion recording (SIR).

Sample preparation
Hydromorphone was extracted from plasma
samples using a solid phase extraction method with
Oasis HLB 1 cc cartridges (Waters). Briefly,
previously frozen plasma samples were thawed and
vortexed and 100 µl was transferred to a 13 x 100
mm glass tube then 60 µl of internal standard (0.1
µg/ml naltrexone) added. Three hundred
microliters of water:methanol (65:35) was added
and tubes were vortexed and allowed to stand for 3
minutes, and then centrifuged for 15 min at 1020 x
g. The supernatant was added to a prewet Oasis
cartridge (1 mL methanol, 1 mL of water) and
washed with 1 mL of 3% methanol in water.
Samples were eluted with 1 mL of 2% formic acid in
acetonitrile:methanol (40:60) and then evaporated
to dryness with nitrogen gas. Samples were
reconstituted in 250 µl of mobile phase and 60 µl
injected into the HPLC system.

Table 2. Inter-assay variability and recovery for hydromorphone in plasma and recovery (n = 5)
Concentration
added
(ng/mL)

Accuracy (%)

C.V. (%)

Recovery
(%)

3.5

Concentration
measured
(ng/mL)
(mean ± S.D.)
3.4 ± 0.17

39

5.2

100

15

15 ± 1.08

100

7.1

90

35

36 ± 1.41

103

4.0

88

75

74 ± 6.92

99

9.3

88

150

152 ± 6.49

101

4.3

93

350

353 ± 10.38

101

2.9

91

SD: standard deviation; n: number of days; CV: coefficient of variation.

Figure 1. Chromatograms of hydromorphone (A) 25ng/mL spiked plasma standard, (B) bearded
dragon plasma sample 1 h after SC administration, (C) blank bearded dragon sample.

Figure 1. Chromatograms of Naltrexone (I.S.) (A) 25ng/mL spiked plasma sample, (B) bearded
dragon plasma sample 1 h after SC administration, (C) blank bearded dragon sample.

Figure 2. Concentration time profile of
hydromorphone in a bearded dragon after a
0.5 mg/kg subcutaneous dose.

Results & Discussion

Blank plasma samples were prepared in the
same manner as study samples and no endogenous
plasma components interfered with the elution of
the peaks of interest. Fig. 1 shows chromatograms
of a (A) 25ng/mL spiked plasma standard, (B) a
bearded dragon plasma sample 1 h after SC
administration and (C) blank bearded dragon
plasma. Retention times were 4.66 min for
hydromorphone and 10.57 min for naltrexone. For
specificity testing six different blank plasma
samples were used in the pre-validation process.
The plasma peak ratio (area of hydromorphone
divide by the IS area) versus the concentration was
plotted and produced a linear curve, over the
concentration range of 1 – 500 ng/ml, with
resulting correlation coefficients of >0.999. A
typical equation for the calibration curve was y =
0.0081x + 0.0020, where y represents the peak
area ratios of hydromorphone to internal standard
and x represents the plasma concentration of
hydromorphone in ng/mL. Intra and inter-assay
RSD for plasma spiked with specific concentrations
of hydromorphone ranged from 1.2 to 9.3% (Tables
1 and 2). The precision was below the set ± 15% for
all quality control samples.
The recovery (Table 2) for hydromorphone from
spiked plasma was determined by comparing
extracted areas with directly injected analyte areas
and ranged from 88% to 100%. The relative
standard deviation was less than 10% for all values.
The recovery of naltrexone was 90% and its relative
standard deviation was 2.0%. The LOQ was 1 ng/ml
and represents a peak approximately five times
baseline noise.

Conclusions

In conclusion, this analytical procedure was
validated in terms of recovery, linearity, LOQ,
precision, and accuracy. The LOQ and recovery are
more than adequate for use in pharmacokinetic
studies. Our results indicate that this HPLC
procedure is a reproducible method that provides
consistent quantification of hydromorphone in
plasma. The addition of naltrexone as an internal
standard also allows for the correction of intra- and
inter-assay variability. This method has been used
successfully to determine hydromorphone
concentrations in plasma samples at this
institution. Figure 2 is a representative
concentration-time profile from a hydromorphone
pharmacokinetic study conducted in bearded
dragons after receiving a 0.5 mg/kg subcutaneous
dose of hydromorphone.

